Entry into a Material Definitive Agreement

Filing Overview

Registrant: Coeptis Therapeutics Holdings, Inc. (the request metadata identifies Z Squared Inc.; the filing itself names Coeptis Therapeutics Holdings, Inc.)

Filing: Form 8-K, filed August 22, 2023, reporting events beginning August 16, 2023.

Material Transaction

On August 16, 2023, Coeptis entered into an exclusive licensing arrangement with Deverra Therapeutics, Inc. covering patent families and related intellectual property for an allogeneic stem-cell expansion and directed-differentiation platform.

  • The licensed platform is intended to generate immune effector cell types, including natural killer (NK) cells and monocyte/macrophages.
  • Defined applications include unmodified NK-cell therapies for viral infections, relapsed/refractory acute myeloid leukemia, and high-risk myelodysplastic syndromes.
  • The license also covers generation of NK and myeloid cells for engineering with Coeptis’s SNAP-CAR and GEAR technologies.

Consideration and Acquired Assets

  • Cash consideration of approximately $570,000.
  • Issuance of 4,000,000 shares of Coeptis common stock to Deverra.
  • Assumption of certain liabilities related to ongoing clinical trials.
  • Acquisition of certain assets, including two Investigational New Drug applications and two Phase 1 programs evaluating DVX201, an unmodified NK-cell therapy derived from pooled donor CD34+ cells.
  • The programs relate to hematologic malignancies and viral infections and include clinical trials NCT04901416 and NCT04900454.

Financial Metrics, Liquidity, and Debt

The filing does not provide revenue, profit, cash-flow, margin, debt, liquidity, or balance-sheet metrics. It also does not disclose the fair value or accounting treatment of the stock issuance, acquired assets, assumed liabilities, or contingent obligations.

Material Changes and Contingent Obligations

Relative to the prior comparable period, the filing reports a material expansion of Coeptis’s licensed intellectual-property portfolio, clinical-stage assets, and development programs; it does not provide comparable-period financial information.

Under the sublicense arrangement, Coeptis may owe Fred Hutchinson Cancer Research Center specified running royalties and milestone payments if triggered by development activities. The filing does not state the amounts, rates, or triggering conditions.

Outlook, Risks, and Unusual Items

  • The acquired programs remain clinical-stage and may require additional development, regulatory approvals, and funding.
  • Coeptis assumed certain liabilities associated with the ongoing clinical trials.
  • The transaction involves contingent royalties and milestone payments that could increase future development costs.
  • The filing provides no quantitative guidance or forecast.
  • Execution depends on the validity and scope of licensed intellectual property, clinical results, regulatory review, manufacturing capabilities, and successful integration of the acquired programs.

Investor Verification Items

  • Review Exhibits 10.1, 10.2, and 10.3 for license territory, field-of-use restrictions, payment terms, sublicensing rights, termination provisions, indemnities, and assumed liabilities.
  • Verify the number of shares issued, resulting dilution, and the accounting valuation recorded for the 4,000,000-share issuance.
  • Confirm the status, ownership, and regulatory history of the two INDs and Phase 1 trials.
  • Determine the potential royalty and milestone amounts payable to Fred Hutchinson Cancer Research Center.
  • Reconcile the registrant named in the source filing with the request metadata identifying Z Squared Inc.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.